Empowered Funds LLC Purchases Shares of 1,454 Teleflex Incorporated (NYSE:TFX)

Empowered Funds LLC purchased a new stake in Teleflex Incorporated (NYSE:TFX) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 1,454 shares of the medical technology company’s stock, valued at approximately $259,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Simplify Asset Management Inc. bought a new stake in Teleflex in the 3rd quarter valued at $4,800,000. JPMorgan Chase & Co. increased its holdings in Teleflex by 14.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 155,158 shares of the medical technology company’s stock valued at $38,374,000 after acquiring an additional 19,466 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Teleflex by 5.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 108,231 shares of the medical technology company’s stock valued at $19,263,000 after acquiring an additional 5,322 shares during the last quarter. Lecap Asset Management Ltd. bought a new stake in shares of Teleflex in the 4th quarter worth about $729,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Teleflex by 35.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,875 shares of the medical technology company’s stock worth $1,053,000 after buying an additional 1,527 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors.

Teleflex Price Performance

TFX stock opened at $175.43 on Friday. Teleflex Incorporated has a 12 month low of $165.62 and a 12 month high of $249.90. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The company has a 50-day moving average price of $177.07 and a 200 day moving average price of $207.80. The stock has a market cap of $8.15 billion, a PE ratio of 34.88, a P/E/G ratio of 1.73 and a beta of 1.16.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TFX. Mizuho reduced their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Truist Financial reduced their target price on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Royal Bank of Canada reduced their target price on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Teleflex has a consensus rating of “Moderate Buy” and a consensus target price of $252.50.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.